FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
- 26 August 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (10), 1426-1434
- https://doi.org/10.1016/s1470-2045(16)30269-8
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cetuximab or bevacizumab in metastatic colorectal cancer?The Lancet Oncology, 2014
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal CancerJournal of Clinical Oncology, 2014
- Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal CancerOncology, 2014
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2013
- Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trialCancer Science, 2013
- Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trialActa Oncologica, 2012
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000